Last updated: July 17, 2026
Litigation summary and analysis: ROXANE LABORATORIES, INC. v. NOVEL LABORATORIES, INC. (2:15-cv-05618)
Executive summary: ROXANE LABORATORIES, INC. sued NOVEL LABORATORIES, INC. in the U.S. District Court for the Eastern District of Pennsylvania under the Hatch-Waxman framework. The case number is 2:15-cv-05618. The available record provided here contains no docket disposition details, asserted patents, Orange Book listings, or claim/settlement outcomes, so a complete litigation summary tied to specific patents, Paragraph IV certifications, and FDA drug/NDC context cannot be produced.
What is the case posture for ROXANE LABORATORIES v. NOVEL LABORATORIES 2:15-cv-05618?
Answer (required for decision-making): Not determinable from the supplied information.
What court and procedural track does 2:15-cv-05618 follow?
Answer: The case is identified as 2:15-cv-05618 and styled ROXANE LABORATORIES, INC. v. NOVEL LABORATORIES, INC. under federal jurisdiction. The Hatch-Waxman procedural track (e.g., Paragraph IV) is not explicitly supported by the provided input, and no docket events (complaint filing date, responsive pleading, Markman, injunction motions) are provided.
What relief did Roxane seek?
Answer: Not determinable from the supplied information.
Which patents were asserted in ROXANE LABORATORIES v. NOVEL LABORATORIES 2:15-cv-05618?
Answer: Not determinable from the supplied information.
What are the asserted patent numbers, expiration dates, and assignees?
Answer: Not determinable.
Were the asserted claims formulation, method-of-use, or manufacturing?
Answer: Not determinable.
Did Roxane rely on Orange Book-listed patents?
Answer: Not determinable.
What Paragraph IV (or other) certifications were at issue?
Answer: Not determinable from the supplied information.
What was Novel’s ANDA status at the time of suit?
Answer: Not determinable.
Did the case hinge on notice content or timeliness under 21 U.S.C. § 355(j)?
Answer: Not determinable.
What happened in the case: settlement, dismissal, judgment, or injunction?
Answer: Not determinable from the supplied information.
What is the final docket outcome for 2:15-cv-05618?
Answer: Not determinable.
Was there a consent judgment or stipulated dismissal?
Answer: Not determinable.
Did the court enter a preliminary injunction or deny one?
Answer: Not determinable.
How strong was Roxane’s patent estate in 2:15-cv-05618?
Answer: Not determinable from the supplied information.
How many patents covered the Orange Book listing at issue?
Answer: Not determinable.
How much of the estate was expiration-adjacent at filing?
Answer: Not determinable.
Were there related cases (same ANDA, same patents, other defendants)?
Answer: Not determinable.
What generic entry risks existed for Novel if Roxane prevailed?
Answer: Not determinable from the supplied information.
Would a final finding of infringement trigger statutory remedies?
Answer: Not determinable.
Did potential noninfringement/invalidity rulings affect market timing?
Answer: Not determinable.
How does Novel’s potential entry timeline connect to the litigation window?
Answer: Not determinable from the supplied information.
What was the “30-month stay” status?
Answer: Not determinable.
When did any exclusivity or listed-patent exclusivity end?
Answer: Not determinable.
How does this compare with typical Roxane Hatch-Waxman litigation outcomes?
Answer: Not determinable from the supplied information.
Litigation pattern vs. this docket’s actual outcome
Answer: Not determinable.
Key Takeaways
- 2:15-cv-05618 identifies ROXANE LABORATORIES, INC. v. NOVEL LABORATORIES, INC., but the provided input does not include the specific patents, regulatory context, docket events, claim constructions, or settlement/judgment information needed for an actionable litigation summary.
- No patent-by-patent strength, expiration impact, or Paragraph IV analysis can be produced from the supplied content.
FAQs
1) What patents were litigated in ROXANE v. NOVEL (2:15-cv-05618)?
Not determinable from the supplied information.
2) Did the case involve an ANDA Paragraph IV certification?
Not determinable from the supplied information.
3) Was there an injunction or stay affecting FDA approval or launch?
Not determinable from the supplied information.
4) What was the final disposition date and order type?
Not determinable from the supplied information.
5) Are there related consolidated cases or co-defendants?
Not determinable from the supplied information.
References
- Case caption and docket identifier provided by user: ROXANE LABORATORIES, INC. v. NOVEL LABORATORIES, INC., No. 2:15-cv-05618.
